Fundraising FoxMabvax Therapeutics Holdings
San Diego, US · Delaware corporation
Find your way into Mabvax Therapeutics Holdings
2 people in our graph can introduce you to the Mabvax Therapeutics Holdings team.
Sign up to see every warm intro you have to Mabvax Therapeutics Holdings
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mabvax Therapeutics Holdings team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JD
J. David HansenPresident, Chief Executive Officer and Chairman of the BoardJ. David Hansen co-founded MabVax Therapeutics in 2006 and has served as its President and Chief Executive Officer. He previously held executive roles at Avanir Pharmaceuticals (including President and Chief Operations Officer of subsidiary Xenerex Biosciences) and Dura Pharmaceuticals, with additional management experience at Merck, Key Pharmaceuticals, and Bristol Myers Squibb.
GH
Gregory HansonChief Financial Officer
MM
Michael M. WickExecutive
WP
William P. KaplanExecutive
SR
Steven R. SchowExecutive
WK
Wendy K. WeeExecutive
Board
JR
Jeffrey RavetchBoard director
KC
Kenneth CohenBoard director
RH
Robert HoffmanBoard director
PL
Philip LivingstonBoard director
TV
Thomas VarranoBoard director
PM
Paul MaierBoard director
Reported raises · per SEC filings
Form D private placements$40.1M disclosed across 7 rounds · 2014–2018
▶$830KraisedMay 2018 · 11 investors · BiotechnologyRule 506(b)
▶$830KraisedMay 2018 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul V. MaierDirector
- Thomas C. VarvaroDirector
- J. David HansenExecutive Officer, Director
- Philip O. LivingstonDirector
- Gregory P. HansonExecutive Officer
- Paul ResnickExecutive Officer
- Jeffrey F. EisenbergDirector
- Kenneth M. CohenDirector
- Paul W. MaffuidExecutive Officer
- Offering amount
- $860K
- Amount sold
- $830K
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedFeb 2018 · 13 investors · BiotechnologyRule 506(b)
▶$2.8MraisedFeb 2018 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas VarvaroDirector
- Paul ResnickExecutive Officer
- Philip LivingstonDirector
- Kenneth CohenDirector
- Paul MaierDirector
- Gregory HansonExecutive Officer
- Paul MaffuidExecutive Officer
- J. David HansenExecutive Officer, Director
- Jeffrey EisenbergDirector
- Offering amount
- $2.8M
- Amount sold
- $2.8M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.6MraisedApr 2015 · 49 investors · BiotechnologyRule 506(b)
▶$11.6MraisedApr 2015 · 49 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey RavetchDirector
- Kenneth CohenDirector
- Gregory HansonExecutive Officer, Director
- Robert HoffmanDirector
- J. David HansenExecutive Officer, Director
- Philip LivingstonDirector
- Thomas VarranoDirector
- Paul MaierDirector
- Offering amount
- $15M
- Amount sold
- $11.6M
- Sales commissions
- $573.7K
- Placement agents
- Laidlaw & Company, Ltd., Palladium Capital Advisors, LLC
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedJul 2014 · 23 investors · BiotechnologyRule 506(b)
▶$3MraisedJul 2014 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- J. DAVID HANSENExecutive Officer, Director
- PHILIP O. LIVINGSTONExecutive Officer, Director
- JEFFREY V. RAVETCHDirector
- GREGORY P. HANSONExecutive Officer
- PAUL MAIERDirector
- KENNETH M. COHENDirector
- JIM J. ANTONOPOULOSDirector
- Offering amount
- $10M
- Amount sold
- $3M
- Sales commissions
- $800K
- Placement agents
- DAWSON JAMES SECURITIES, INC., PALLADIUM CAPITAL ADVISORS, LLC, H.C. WAINWRIGHT & CO. LLC
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedJul 2014 · 55 investors · BiotechnologyRule 506(b)
▶$5.2MraisedJul 2014 · 55 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Philip O. LivingstonExecutive Officer, Director
- Kenneth M. CohenDirector
- Jeffrey V. RavetchDirector
- J. David HansenExecutive Officer, Director
- Michael WickDirector
- Gregory P. HansonExecutive Officer
- Paul MaierDirector
- Jim J. AntonopoulosDirector
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.6MraisedMay 2014 · 3 investors · BiotechnologyRule 506(b)
▶$4.6MraisedMay 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward W. CantrallDirector
- Michael M. WickExecutive Officer, Director
- William P. KaplanExecutive Officer
- Richard B. NewmanDirector
- Steven R. GoldringDirector
- Steven R. SchowExecutive Officer
- Wendy K. WeeExecutive Officer
- Offering amount
- $4.6M
- Amount sold
- $4.6M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.1MraisedFeb 2014 · 15 investors · BiotechnologyRule 506(b)
▶$12.1MraisedFeb 2014 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James AntonopoulosDirector
- J. David HansenExecutive Officer, Director
- Philip O. LivingstonDirector
- Offering amount
- $15.1M
- Amount sold
- $12.1M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded Mabvax Therapeutics Holdings?
- Mabvax Therapeutics Holdings was founded by J. David Hansen.
- How much funding has Mabvax Therapeutics Holdings raised?
- Mabvax Therapeutics Holdings has disclosed $40.1M raised across 7 rounds.
- Where is Mabvax Therapeutics Holdings headquartered?
- Mabvax Therapeutics Holdings is headquartered in San Diego, US.